Definitive Healthcare Corp. (NASDAQ:DH - Get Free Report) shares rose 4.7% on Tuesday . The stock traded as high as $3.89 and last traded at $3.94. Approximately 172,040 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 787,582 shares. The stock had previously closed at $3.76.
Wall Street Analysts Forecast Growth
DH has been the subject of several recent analyst reports. The Goldman Sachs Group raised their target price on shares of Definitive Healthcare from $3.00 to $3.40 and gave the company a "neutral" rating in a research note on Monday, May 12th. Wall Street Zen lowered shares of Definitive Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, May 31st. BTIG Research lowered shares of Definitive Healthcare from a "buy" rating to a "neutral" rating in a report on Friday, May 9th. Finally, Barclays dropped their price objective on shares of Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating on the stock in a report on Monday, March 3rd. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $5.10.
Read Our Latest Report on DH
Definitive Healthcare Stock Up 0.9%
The firm has a market cap of $564.10 million, a PE ratio of -1.22, a PEG ratio of 4.06 and a beta of 1.58. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49. The business's 50 day moving average price is $3.07 and its 200 day moving average price is $3.70.
Definitive Healthcare (NASDAQ:DH - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. The company had revenue of $59.19 million during the quarter, compared to analysts' expectations of $56.20 million. During the same quarter in the prior year, the company earned $0.08 EPS. Definitive Healthcare's revenue was down 6.8% compared to the same quarter last year. On average, equities research analysts expect that Definitive Healthcare Corp. will post 0.16 earnings per share for the current year.
Institutional Trading of Definitive Healthcare
Several hedge funds have recently made changes to their positions in DH. Goldman Sachs Group Inc. grew its stake in shares of Definitive Healthcare by 564.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company's stock valued at $25,191,000 after buying an additional 7,404,363 shares during the period. Whetstone Capital Advisors LLC purchased a new position in shares of Definitive Healthcare during the 1st quarter worth approximately $2,512,000. Irenic Capital Management LP boosted its position in shares of Definitive Healthcare by 9.2% during the 4th quarter. Irenic Capital Management LP now owns 7,003,194 shares of the company's stock worth $28,783,000 after purchasing an additional 590,009 shares during the period. Susquehanna Fundamental Investments LLC purchased a new position in shares of Definitive Healthcare during the 4th quarter worth approximately $1,181,000. Finally, Two Sigma Investments LP boosted its position in shares of Definitive Healthcare by 2,383.1% during the 4th quarter. Two Sigma Investments LP now owns 285,555 shares of the company's stock worth $1,174,000 after purchasing an additional 274,055 shares during the period. Hedge funds and other institutional investors own 98.67% of the company's stock.
About Definitive Healthcare
(
Get Free Report)
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Definitive Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Definitive Healthcare wasn't on the list.
While Definitive Healthcare currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
